Cross-reactive antibody responses to the 2009 A/H1N1v influenza virus in the Italian population in the pre-pandemic period.
about
Incidence of H1N1 2009 virus infection through the analysis of paired plasma specimens among blood donors, FranceSchool closure policies at municipality level for mitigating influenza spread: a model-based evaluationEstimating age-specific cumulative incidence for the 2009 influenza pandemic: a meta-analysis of A(H1N1)pdm09 serological studies from 19 countries.Two years after pandemic influenza A/2009/H1N1: what have we learned?The community impact of the 2009 influenza pandemic in the WHO European region: a comparison with historical seasonal data from 28 countries.Prevalence of antibodies against seasonal influenza A and B viruses during the 2009-2010 and 2010-2011 influenza seasons in residents of Pittsburgh, PA, USASeroprevalence to influenza A(H1N1) 2009 virus--where are we?Pandemic influenza A/H1N1pdm in Italy: age, risk and population susceptibility.Epidemiological characterization of influenza A(H1N1)pdm09 cases from 2009 to 2010 in Baguio City, the Philippines.Serological and virological surveillance of avian influenza A virus H9N2 subtype in humans and poultry in Shanghai, China, between 2008 and 2010Difference in immune response in vaccinated and unvaccinated Swedish individuals after the 2009 influenza pandemicThe role of different social contexts in shaping influenza transmission during the 2009 pandemicAn open-label, randomized clinical trial assessing immunogenicity, safety and tolerability of pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially or simultaneously with seasonal virosomal-adjuvanted influenza vaccine to paediCD8+ T cell immunity to 2009 pandemic and seasonal H1N1 influenza virusesRetrospective investigation of an influenza A/H1N1pdm outbreak in an Italian military ship cruising in the Mediterranean Sea, May-September 2009Immuno-epidemiologic correlates of pandemic H1N1 surveillance observations: higher antibody and lower cell-mediated immune responses with advanced age.Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination.The effect of risk perception on the 2009 H1N1 pandemic influenza dynamics.Sensitivity and specificity of serologic assays for detection of human infection with 2009 pandemic H1N1 virus in U.S. populations.Systematic review of clinical and epidemiological features of the pandemic influenza A (H1N1) 2009Prevalence of antibodies to 2009 pandemic influenza A (H1N1) virus in German adult population in pre- and post-pandemic period.Case-control study of risk factors for hospitalization caused by pandemic (H1N1) 2009.The age-specific cumulative incidence of infection with pandemic influenza H1N1 2009 was similar in various countries prior to vaccinationPost-pandemic seroprevalence of pandemic influenza A (H1N1) 2009 infection (swine flu) among children <18 years in Germany.Pandemic influenza due to pH1N1/2009 virus: estimation of infection burden in Reunion Island through a prospective serosurvey, austral winter 2009.Boosting heterosubtypic neutralization antibodies in recipients of 2009 pandemic H1N1 influenza vaccine.A new approach to characterising infectious disease transmission dynamics from sentinel surveillance: application to the Italian 2009-2010 A/H1N1 influenza pandemicSeroprevalence study of antibodies against influenza A(H1N1) 2009 virus after the second pandemic wave in Slovenia.Influenza serological studies to inform public health action: best practices to optimise timing, quality and reporting.Immunogenicity and tolerability after two doses of non-adjuvanted, whole-virion pandemic influenza A (H1N1) vaccine in HIV-infected individuals.Searching for sharp drops in the incidence of pandemic A/H1N1 influenza by single year of age.Antibody responses against influenza A(H1N1)pdm09 virus after sequential vaccination with pandemic and seasonal influenza vaccines in Finnish healthcare professionals.Cross-reactive antibody response to the pandemic A (H1N1) 2009 influenza virus induced by vaccination with a seasonal trivalent influenza vaccine: a longitudinal study of three influenza seasons in Japan.Prevalence of seropositivity to pandemic influenza A/H1N1 virus in the United States following the 2009 pandemicH3N2v and other influenza epidemic risk based on age-specific estimates of sero-protection and contact network interactions.Pre-existing immunity with high neutralizing activity to 2009 pandemic H1N1 influenza virus in Shanghai population.2009 A(H1N1) seroconversion rates and risk factors among the general population in Vientiane Capital, Laos.Seroprevalence of antibodies to influenza A/H1N1/2009 among transmission risk groups after the second wave in Mexico, by a virus-free ELISA method.Reliability of pseudotyped influenza viral particles in neutralizing antibody detectionAvian influenza virus H9N2 seroprevalence and risk factors for infection in occupational poultry-exposed workers in Tai'an of China.
P2860
Q28730980-F1CD8527-19C4-45E5-BDC5-2101F824E70BQ30151697-61370714-F153-4DD3-A7D7-D148E54430BCQ30223476-719A1F80-DBEC-4EBD-884E-667EAD504C36Q30224656-EC081D2D-33C7-4EBD-8449-1CB82BA12DA3Q30224750-8D7F5648-B6DA-4508-9C72-D855DC849B9EQ30224919-C1F87139-473E-4B44-AE25-2AEE592FDE86Q30226546-437458D1-E9CF-4DF0-BE85-91BDAC61DEF8Q30354383-E7C80239-6B74-444B-B899-3C6E6A9BD315Q30355708-1C28F2F6-A947-463E-8EBB-1BF769BCDA67Q30362291-C4D7AF00-7DA4-4C39-9797-408DC41A4134Q30363471-F78D0033-273C-4638-8A86-FAA2BEE35893Q30368968-103EB6BA-A64C-4F40-AAB5-B3C7E837D237Q30395254-71F5D319-7505-4DB1-BC1E-FFF47914DC12Q30398319-B717DA09-7164-4319-B434-5461F5E611B9Q30399178-7DDEFA37-1BDD-426E-8F13-C96AE4F5495EQ30399272-B8757A97-B362-477F-B512-5BAA6042F879Q30399474-EF3E1E7A-2C0C-4094-A169-ABC049D07F7AQ30399791-87324EB1-E4E3-4547-B9E5-3BBD346FDF56Q30401611-FD69D297-9AC4-4120-82A2-C3BD63956E03Q30401654-7E60E279-9741-4AAA-9DD8-F56F6AFAB521Q30404184-0D677577-D51D-4819-801E-176854FAB232Q30405388-AC8F2F48-2CA1-4D27-B6EB-2265E9866E43Q30406109-32199C8D-99A3-4867-8D32-5739408207CCQ30407047-49C9152D-D5E3-4E42-937B-8518C70BEBF7Q30407929-5871A444-8E83-494D-9ED3-F23D5B25BFB4Q30408974-E8A13594-2D3D-4B0F-82BC-56B19CB17630Q30412909-25C9284F-B1FD-457F-810C-C43905851CF4Q30412979-3FFA1831-538B-41BA-9584-13E79FFB71B3Q30416214-A60D5840-2E1B-4647-BC63-52BB0B037FAEQ30417245-4BC1DAAD-9357-41AE-9EE5-01CBDC8462DAQ30420192-6DC5E5EE-BB44-4B9A-B0A8-9888468B3347Q30420571-F218957D-C12C-412B-9B2B-3DFEE6E34A92Q30421614-82732BE3-A8BB-4B6C-BE05-EDAFC4827FC8Q30423135-03CCAA82-4A77-406B-81EE-A117992A189EQ30426038-CB92DA8D-8DDC-4BBE-B237-0CEB24740F4BQ30428692-18233AF6-85FF-4AF6-A189-67AA385F729FQ30430052-2D147A23-433E-4F90-8546-93E113CB4A70Q33698250-AB5048EC-823D-48FB-8F9F-40EF9A7E9B8AQ34600142-F79984D1-3F09-46CE-B63B-4A5816002036Q40816187-2077E48D-2CED-4ED3-A251-156449EB402C
P2860
Cross-reactive antibody responses to the 2009 A/H1N1v influenza virus in the Italian population in the pre-pandemic period.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Cross-reactive antibody respon ...... on in the pre-pandemic period.
@ast
Cross-reactive antibody respon ...... on in the pre-pandemic period.
@en
type
label
Cross-reactive antibody respon ...... on in the pre-pandemic period.
@ast
Cross-reactive antibody respon ...... on in the pre-pandemic period.
@en
prefLabel
Cross-reactive antibody respon ...... on in the pre-pandemic period.
@ast
Cross-reactive antibody respon ...... on in the pre-pandemic period.
@en
P2093
P50
P921
P1433
P1476
Cross-reactive antibody respon ...... on in the pre-pandemic period.
@en
P2093
Antonino Bella
Giulia Lapini
Simona Piccirella
Stefania Salmaso
P304
P356
10.1016/J.VACCINE.2010.03.006
P407
P50
P577
2010-03-20T00:00:00Z